Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.
US-based gene therapy developer 4D Molecular Therapeutics (4DMT) refiled for an initial public offering on Tuesday, giving Berkeley Catalyst Fund, a venture unit aligned with University of California, the chance to exit.
The company has filed to raise up to $75m in an offering on the Nasdaq Global Market, the same market where it originally filed for a $100m IPO in September 2019 before withdrawing that application in July. Goldman Sachs, BofA Securities and Evercore Group are…
